X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs MERCK LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES MERCK LTD DIVIS LABORATORIES/
MERCK LTD
 
P/E (TTM) x 31.4 33.3 94.2% View Chart
P/BV x 5.4 3.7 145.7% View Chart
Dividend Yield % 0.9 0.8 120.2%  

Financials

 DIVIS LABORATORIES   MERCK LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
MERCK LTD
Dec-16
DIVIS LABORATORIES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,2221,060 115.3%   
Low Rs784623 125.8%   
Sales per share (Unadj.) Rs153.1632.4 24.2%  
Earnings per share (Unadj.) Rs39.945.7 87.4%  
Cash flow per share (Unadj.) Rs44.662.3 71.6%  
Dividends per share (Unadj.) Rs10.0011.00 90.9%  
Dividend yield (eoy) %1.01.3 76.3%  
Book value per share (Unadj.) Rs201.8388.8 51.9%  
Shares outstanding (eoy) m265.4716.60 1,599.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.3 492.4%   
Avg P/E ratio x25.118.4 136.4%  
P/CF ratio (eoy) x22.513.5 166.6%  
Price / Book Value ratio x5.02.2 229.7%  
Dividend payout %25.024.1 104.0%   
Avg Mkt Cap Rs m266,26613,969 1,906.1%   
No. of employees `0009.71.6 615.0%   
Total wages/salary Rs m4,6871,487 315.3%   
Avg. sales/employee Rs Th4,175.06,631.9 63.0%   
Avg. wages/employee Rs Th481.5939.2 51.3%   
Avg. net profit/employee Rs Th1,089.3479.4 227.2%   
INCOME DATA
Net Sales Rs m40,64310,498 387.1%  
Other income Rs m749242 309.0%   
Total revenues Rs m41,39210,741 385.4%   
Gross profit Rs m14,4601,135 1,273.7%  
Depreciation Rs m1,233276 447.7%   
Interest Rs m230-   
Profit before tax Rs m13,9531,102 1,266.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349343 975.6%   
Profit after tax Rs m10,604759 1,397.3%  
Gross profit margin %35.610.8 329.0%  
Effective tax rate %24.031.1 77.1%   
Net profit margin %26.17.2 360.9%  
BALANCE SHEET DATA
Current assets Rs m40,1056,410 625.7%   
Current liabilities Rs m6,5958,828 74.7%   
Net working cap to sales %82.5-23.0 -357.9%  
Current ratio x6.10.7 837.7%  
Inventory Days Days11958 205.5%  
Debtors Days Days8138 210.2%  
Net fixed assets Rs m19,9951,406 1,421.7%   
Share capital Rs m531166 319.8%   
"Free" reserves Rs m53,0436,286 843.8%   
Net worth Rs m53,5746,455 830.0%   
Long term debt Rs m00-   
Total assets Rs m61,5858,828 697.6%  
Interest coverage x618.4NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.2 55.5%   
Return on assets %17.38.6 200.7%  
Return on equity %19.811.8 168.3%  
Return on capital %26.117.1 152.8%  
Exports to sales %08.3 0.0%   
Imports to sales %25.221.0 120.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs m10,2592,209 464.4%   
Fx inflow Rs m35,384959 3,690.4%   
Fx outflow Rs m10,3992,612 398.1%   
Net fx Rs m24,985-1,653 -1,511.3%   
CASH FLOW
From Operations Rs m11,4931,070 1,073.7%  
From Investments Rs m-11,372-750 1,516.8%  
From Financial Activity Rs m-93-150 62.1%  
Net Cashflow Rs m28171 16.6%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 11.8 18.2 64.8%  
FIIs % 19.0 1.0 1,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 29.1 59.1%  
Shareholders   31,796 28,591 111.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 24, 2018 09:17 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - STERLING BIOTECH COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS